Neoplasms Clinical Trial
— ACEOfficial title:
The Alberta Cancer Exercise "ACE" Program for Cancer Survivors: Supporting Community-based Exercise Participation for Health Promotion and Secondary Cancer Prevention
The primary purpose of this proposed 5-year hybrid effectiveness and implementation study is to evaluate the relative benefit from, and implementation of an Alberta wide clinic-to-community-based cancer and exercise model of care - the Alberta Cancer Exercise (ACE) Program. The investigators hypothesize that the strategy will improve the physical well-being and QoL of survivors (on and off cancer treatment) while preventing the development of secondary cancers.
Status | Recruiting |
Enrollment | 2500 |
Est. completion date | June 30, 2024 |
Est. primary completion date | March 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. have a diagnosis of cancer; 2. be over the age of 18 years; 3. be able to participate in low-intensity levels of activity at minimum; 4. be pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), or have received cancer treatment within the past 3 years; or have ongoing significant cancer or treatment-related impairments (requiring supportive exercise intervention); 5. be able to provide informed written consent in English. Exclusion criteria: 1) Inability or deemed unsafe to participate in physical activity program - |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary/ Tom Baker Cancer Centre | Calgary | Alberta |
Canada | University of Alberta & Cross Cancer Institute | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | Alberta Health services, Cross Cancer Institute, Tom Baker Cancer Centre, University of Calgary |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Home-based programming stepping test | 2-minute stepping test | Baseline to One-year | |
Other | 1RM or 8RM strength (optional) | Change in bench press, vertical row and leg press strength (kg) | Baseline to One-year | |
Other | Muscular endurance test (optional) | Change in number of push-ups | Baseline to One-year | |
Other | Core endurance test (optional) | Change in plank test (seconds held) | Baseline to One-year | |
Primary | Physical Activity Minutes Per Week | Change in number of participants meeting Guidelines for Physical Activity of 150 minutes per week of moderate intensity exercise | Baseline to One-year | |
Secondary | Aerobic Endurance | Change in 6 minute walk test distance (metres) | Baseline to One-year | |
Secondary | Quality of Life Cancer Specific | Change in Functional Assessment of Cancer Therapy General Scale | Baseline to One year | |
Secondary | General Health-related Quality of Life | Change in Rand Short Form (SF)-36 | Baseline to One-year | |
Secondary | Fatigue | FACT-Fatigue subscale | Baseline to One-year | |
Secondary | Upper extremity grip strength | Change in hand-grip dynamometry (kg) | Baseline to One-year | |
Secondary | Functional performance test | Change in sit-to-stand (number in 30 seconds) | Baseline to One-year | |
Secondary | Upper extremity flexibility | Change in active shoulder flexion range of motion (degrees) | Baseline to One-year | |
Secondary | Lower extremity flexibility | Change in sit-and-reach test (cm) | Baseline to One-year | |
Secondary | Balance | Change in one legged stance test (seconds) | Baseline to One-year | |
Secondary | Cost-effectiveness evaluation | EQ-5D questionnaire | Baseline to One-year | |
Secondary | Exercise adherence | Adherence to exercise programming (attendance at sessions) | Baseline to 12-weeks | |
Secondary | Body Composition | Change in BMI | Baseline to One-year | |
Secondary | Waist and hip measurements | Change in waist and hip circumference (cm) and change in waist-to-hip ratio | Baseline to One-year | |
Secondary | Program implementation and evaluation | RE-AIM: program reach, effectiveness, adoption, implementation and maintenance | Baseline to One-year | |
Secondary | Adverse events | Adverse event rates | Baseline to One-year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |